natgillin/translations-raw huggingface dataset:
The use of 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required for the infusion when the concentrate for infusion is diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion.
Če je koncentrat za infundiranje razredčen z 0,9-% (9 mg/ml) raztopino natrijevega klorida za infundiranje, je treba za infundiranje uporabiti 0,20- ali 0,22-mikronski polietersulfonski (PES) filter v liniji.
The use of 150 mg tablets to achieve the recommended dose is appropriate when there is a possibility of hypersensitivity to specific colouring agents, or difficulty in swallowing the 300 mg or 600 mg tablets.
Uporaba 150 mg tablet za doseganje priporočenega odmerka je primerna kadar obstaja možnost preobčutljivosti na barvila v 300 mg ali 600 mg tabletah ali če jih bolnik ne more pogoltniti.
The use of 64Cu-labelled medicinal products is contraindicated during established or suspected pregnancy or when pregnancy has not been excluded (see section 4.3).
Uporaba z bakrom (64Cu) označenih zdravil je kontraindicirana ob ugotovljeni nosečnosti ali sumu nanjo ali kadar nosečnost ni bila izključena (glejte poglavje 4.
The use of 64Cu-labelled medicines involves exposure to small amounts of radioactivity.
Uporaba zdravil, označenih z bakrom (64Cu), vključuje izpostavljenost majhnim količinam radioaktivnosti.
The use of 75 and 150 mg tablets to achieve the recommended dose is appropriate when there is a possibility of hypersensitivity to specific colouring agents, or difficulty in swallowing the 300 mg tablets.
Uporaba 75 mg in 150 mg tablet za doseganje priporočenega odmerka je primerna kadar obstaja možnost preobčutljivosti na barvila v 300 mg tabletah ali če jih bolnik ne more pogoltniti.
The use of 75 and 150 mg tablets to achieve the recommended dose is appropriate when there is a possibility of hypersensitivity to specific colouring agents, or difficulty in swallowing the 600 mg tablets.
Uporaba 75 mg in 150 mg tablet za doseganje priporočenega odmerka je primerna kadar obstaja možnost preobčutljivosti na barvila v 600 mg tabletah ali če jih bolnik ne more pogoltniti.
The use of 75 mg tablets to achieve the recommended dose is appropriate when there is a possibility of hypersensitivity to specific colouring agents, or difficulty in swallowing the 300 mg or 600 mg tablets.
Uporaba 75 mg tablet za doseganje priporočenega odmerka je primerna kadar obstaja možnost preobčutljivosti na barvila v 300 mg ali 600 mg tabletah ali če jih bolnik ne more pogoltniti.
The use of a clean application aid is recommended and contact with other parts of the body should be avoided.
Priporočamo uporabo čistega pripomočka za nanašanje gela in pri tem se morate izogibati stiku z drugimi deli telesa.
The use of a once-daily dosing should be limited to those adult patients having only very few protease inhibitor (PI) associated mutations (i.e. less than 3 PI mutations in line with clinical trial results, see section 5.1 for the full description of the population) and should take into account the risk of a lesser sustainability of the virologic suppression (see section 5.1) and higher risk of diarrhoea (see section 4.8) compared to the recommended standard twice-daily dosing.
Uporabo enkrat na dan je treba omejiti na odrasle, ki imajo le zelo malo mutacij, povezanih z zaviralci proteaz (manj kot 3 takšne mutacije v skladu z rezultati klinične študije; za celoten opis populacije glejte poglavje 5.1), in upoštevati je treba tveganje manjše stalnosti virološke supresije (glejte poglavje 5.1) in večje tveganje driske (glejte poglavje 4.8) v primerjavi s priporočeno standardno uporabo dvakrat na dan.
The use of ABASAGLAR may be considered during pregnancy, if necessary.
Med nosečnostjo je treba uporabo zdravila ABASAGLAR, če je potrebna, presoditi.
The use of Aclasta in children and adolescents has not been studied.
Uporabe zdravila Aclasta pri otrocih in mladostnikih niso proučevali.
The use of Aclasta in patients with severe renal impairment (creatinine clearance < 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Uporaba zdravila Aclasta je pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 35 ml/min) kontraindicirana zaradi povečanega tveganja za odpoved ledvic pri tej populaciji.
The use of Actelsar HCT in children and adolescents up to the age of 18 years is not recommended.
Uporabe zdravila Actelsar HCT pri otrocih in mladostnikih do 18. leta ne priporočamo.
The use of Adempas in children and adolescents (under 18 years of age) should be avoided.
Uporabi zdravila Adempas pri otrocih in mladostnikih (starih manj kot 18 let) se je treba izogibati.
The use of Advagraf is not recommended in children and adolescents under 18 years.
Uporaba zdravila Advagraf ni priporočljiva pri otrocih in mladostnikih, mlajših od 18 let.
The use of Aerivio Spiromax follows three simple steps: open, breathe and close which are outlined below.
Zdravilo Aerivio Spiromax se uporablja v treh preprostih korakih: odprite, vdihnite in zaprite, kot je opisano spodaj.
The use of Aerivio Spiromax follows three simple steps: open, breathe and close which are outlined below.
Zdravilo Airexar Spiromax se uporablja v treh preprostih korakih: odprite, vdihnite in zaprite, kot je opisano spodaj.
The use of Agenerase together with ritonavir has not been studied in patients with liver disease.
Uporaba zdravila Agenerase skupaj z ritonavirjem pri bolnikih z jetrno boleznijo ni bila raziskana.
The use of alcohol during Lojuxta treatment is not recommended.
Uporaba alkohola med zdravljenjem z zdravilom Lojuxta ni priporočljiva.
The use of aliskiren in combination with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see section 4.3).
Pri bolnikih s sladkorno boleznijo ali okvaro ledvic (GFR < 60 ml/min/1,73 m2) je sočasna uporaba aliskirena in zaviralcev angiotenzinskih receptorjev II ali zaviralcev ACE kontraindicirana (glejte poglavje 4.3).
The use of aliskiren in combination with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see section 4.3).
Pri bolnikih s sladkorno boleznijo ali okvaro ledvic (GFR <60 ml/min/1,73 m2) je sočasna uporaba aliskirena in zaviralcev angiotenzinskih receptorjev II ali zaviralcev ACE kontraindicirana (glejte poglavje 4.3).
The use of amifampridine in patients with the non- paraneoplastic form of LEMS should only be commenced following a thorough assessment of the risk- benefit to the patient.
Uporaba amifampridina pri bolnikih z neparaneoplastično obliko LEMS se lahko začne šele po temeljiti oceni koristi in tveganj za bolnika.
The use of an additional contraceptive method is recommended to prevent possible failure of oral contraception that could occur in case of severe diarrhoea (see section 4.5).
Ker je med hudo drisko peroralna kontracepcija lahko neučinkovita, je v tem primeru priporočljiva uporaba dodatne kontracepcijske metode (glejte poglavje 4.5).
The use of an additional contraceptive method is recommended to prevent possible failure of oral contraception that could occur in case of severe diarrhoea (see sections 4.4 and 4.5).
Priporočena je uvedba dodatne kontracepcijske metode, da se prepreči morebitno neučinkovitost peroralnih kontracepcijskih sredstev do česar bi lahko prišlo v primeru hude driske (glejte poglavji 4.4 in 4.5)
The use of an infusion pump or syringe driver (if needed),
uporabi infuzijske črpalke ali pripomočka za injiciranje (če sta potrebna),
The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section 4.4).
Uporaba antagonistov angiotenzina II v prvem trimesečju nosečnosti ni priporočljiva (glejte
The use of ANORO has not been studied in patients with severe hepatic impairment and should be used with caution.
Uporaba zdravila ANORO ni raziskana pri bolnikih s hudo okvaro jeter, zato ga je pri takšnih bolnikih treba uporabljati previdno.
The use of antibacterial agents may increase the risk of overgrowth of non-susceptible micro- organisms.
Uporaba protibakterijskih zdravil lahko poveča tveganje pretirane rasti nedovzetnih mikroorganizmov.
The use of antibiotics may promote the overgrowth of non-susceptible micro-organisms.
Uporaba antibiotikov lahko pospeši prekomerno rast neobčutljivih mikroorganizmov.
The use of any combined hormonal contraceptive (CHC) increases the risk of venous thromboembolism (VTE) compared with no use.
Uporaba katerega koli kombiniranega hormonskega kontraceptiva (CHC) poveča tveganje za nastanek venske trombembolije (VTE) v primerjavi z ženskami, ki CHC ne uporabljajo.
The use of any combined hormonal contraceptive (CHC) increases the risk of venous thromboembolism (VTE) compared with no use.
Uporaba katerega koli kombiniranega hormonskega kontraceptiva (KPK) poveča tveganje za nastanek venske trombembolije (VTE) v primerjavi z ženskami, ki KPK ne uporabljajo.
The use of any diluent other than 5% (50 mg/ml) glucose solution for infusion, or the presence of any bacteriostatic agent such as benzyl alcohol may cause precipitation of Caelyx.
Uporaba kateregakoli drugega vehikla kot 5% (50 mg/ml) raztopine glukoze za infundiranje oz. prisotnost kakršnegakoli bakteriostatika, npr. benzil alkohola, lahko povzroči obarjanje zdravila Caelyx.
The use of any diluent other than 50 mg/ml (5%) glucose solution for infusion may cause precipitation of PLD. (See also PLD Summary of Product Characteristics for specific handling instructions).
Uporaba drugih redčil kot 50 mg/ml (5-odstotna) raztopina glukoze za infundiranje lahko povzroči obarjanje PLD. (Glejte tudi povzetek glavnih značilnosti zdravila PLD za posebna navodila za ravnanje z zdravilom).
The use of any of these medicines together with Jinarc is to be avoided because this may reduce the effects of Jinarc. diuretics (used to increase your urine production).
Uporabi katerega koli od teh zdravil skupaj z zdravilom Jinarc se je treba izogniti, saj lahko ta zdravila zmanjšajo učinke zdravila Jinarc. diuretiki (uporabljajo se za povečanje nastajanja urina).
The use of auricular preparations may be associated with hearing impairment, usually temporary, and primarily in geriatric dogs.
Nekaterim starejšim psom se je ob dajanju zdravila prehodno poslabšal sluh.
The use of avanafil with Kaletra
in inhalirani ali intranazalni
The use of avanafil with Kaletra
Kaletra s salmeterolom ni
The use of avanafil with lopinavir/ritonavir is contraindicated (see section 4.3).
Sočasna uporaba lopinavirja/ritonavirja in kvetiapina je kontraindicirana, ker lahko poveča toksičnost, povezano s kvetiapinom.
The use of besilesomab is contraindicated in pregnant women (see section 4.3).
Uporaba besilesomaba je kontraindicirana v nosečnosti (glejte poglavje 4.3).
The use of Binocrit in patients scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation programme is contraindicated in patients with severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.
Pri bolnikih, naročenih na večji elektivni ortopedski kirurški poseg in ki niso vključeni v program avtolognega zbiranja krvi, je uporaba zdravila Binocrit kontraindicirana, če imajo hudo koronarno, periferno arterijsko, karotidno ali cerebrovaskularno bolezen ali so nedavno preboleli miokardni infarkt ali cerebrovaskularni dogodek.
The use of BiResp Spiromax follows three simple steps: open, breathe and close which are outlined below.
Uporaba zdravila BiResp Spiromax zajema tri preproste korake: odprite, vdihnite in zaprite, ki so opisani spodaj.
The use of bronchodilator therapy for symptoms was not different between Rapiscan and placebo.
Uporaba zdravljenja simptomov z bronhodilatatorjem se ni razlikovala med zdravilom Rapiscan in placebom.
The use of Budesonide/Formoterol Teva Pharma B.V. follows three simple steps: open, breathe and close which are outlined below.
Uporaba zdravila Budezonid/formoterol Teva Pharma B.V. zajema tri preproste korake: odprite, vdihnite in zaprite, ki so opisani spodaj.
The use of calcium folinate /folinic acid in the management of pemetrexed overdose should be considered.
Pri zdravljenju prevelikega odmerjanja pemetrekseda velja razmisliti o uporabi kalcijevega folinata / folinične kisline.
The use of ceftazidime/avibactam to treat patients with hospital-acquired pneumonia, including ventilator-associated pneumonia, is based on experience with ceftazidime alone and on analyses of the pharmacokinetic-pharmacodynamic relationship for ceftazidime/avibactam.
Uporaba kombinacije ceftazidim/avibaktam za zdravljenje bolnikov z bolnišnično pljučnico, vključno z ventilatorsko pljučnico, temelji le na izkušnjah s samim ceftazidimom in na analizah farmakokinetičnega/farmakodinamičnega razmerja za kombinacijo ceftazidim/avibaktam.
The use of ceftazidime/avibactam to treat patients with infections due to Gram-negative aerobic pathogens who have limited treatment options is based on experience with ceftazidime alone and on analyses of the pharmacokinetic-pharmacodynamic relationship for ceftazidime/avibactam (see section 5.1).
Uporaba ceftazidima/avibaktama za okužbe z gramnegativnimi aerobnimi patogeni pri bolnikih, pri katerih so možnosti zdravljenja omejene, temelji le na izkušnjah s samim ceftazidimom in na analizah farmakokinetičnega/farmakodinamičnega razmerja za kombinacijo ceftazidim/avibaktam (glejte poglavje 5.1).
The use of CELSENTRI in people under the age of 18 has not been proven.
Uporaba zdravila CELSENTRI pri osebah, mlajših od 18 let, ni bila dokazana.
The use of Celvapan may be considered during pregnancy if this is thought to be necessary, taking into account official recommendations.
Če menite, da je potrebno, lahko cepivo Celvapan uporabljate tudi v času nosečnosti, ob upoštevanju uradnih priporočil.
The use of Cerenia solution for injection against vomiting due to motion sickness is not recommended.
Uporabe raztopine za injiciranje Cerenia za preprečevanje bruhanja zaradi vožnje, ne priporočamo.
The use of ChondroCelect has not been studied in this age group.
Uporaba zdravila ChondroCelect pri tej starostni skupini ni bila raziskana.
The use of ChondroCelect is generally not recommended when you are overweight (i.e. a Body Mass Index over 30) because it could compromise the result of the treatment.
Uporaba zdravila ChondroCelect na splošno ni priporočljiva, če imate prekomerno telesno maso (tj. indeks telesne mase nad 30), ker lahko ogrozi rezultat zdravljenja.
The use of ChondroCelect is not recommended in children and adolescents below 18 years.
Zdravilo ChondroCelect se ne priporoča za uporabo pri otrocih in mladostnikih, mlajših od 18 let.
The use of Cinacalcet Mylan in children and adolescents has not been established.
Uporaba zdravila Cinakalcet Mylan pri otrocih in mladostnikih ni preučena.
the use of classical swine fever vaccines is prohibited.
Uporaba cepiv proti klasični prašičji kugi je prepovedana.
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR=43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR=18.2%; CI: 6.5%, 28.3%).
Uporaba klopidogrela v CURE je bila povezana z zmanjšano potrebo po zdravljenju s trombolitiki (zmanjšanje RT= 43,3%; IZ: 24,3%, 57,5%) in inhibitorji glikoproteinov IIb/IIIa (zmanjšanje RT
The use of coagulation tests and their interpretation
Navodilo o uporabi preizkusov strjevanja krvi in interpretaciji izvidov
The use of coagulation tests and their interpretation
opis uporabe koagulacijskih testov in njihova interpretacija
The use of coagulation tests and their interpretation
uporaba koagulacijskih testov in njihova interpretacija
The use of combinations of levodopa and carbidopa is well established, having being in use since the mid- 1970s.
Uporaba kombinacij levodope in karbidope je dobro uveljavljena, in sicer od sredine sedemdesetih let prejšnjega stoletja.
The use of combined hormonal contraceptives has been connected with an increase in the risk of blood clots in the vein (venous thrombosis).
Uporaba kombiniranih hormonskih kontraceptivov je bila povezana z večjim tveganjem za krvne strdke v veni (vensko trombozo).
The use of combined hormonal contraceptives has been connected with an increase in the risk of blood clots in the vein (venous thrombosis).
Uporabo kombiniranih hormonskih kontraceptivov so povezovali z večjim tveganjem krvnih strdkov v venah (venska tromboza).
The use of concomitant CNS-active medicinal products may increase the risk of respiratory depression (see section 4.5).
Sočasna uporaba zdravil, ki delujejo na osrednje živčevje, lahko poveča tveganje za depresijo dihanja (glejte poglavje 4.5).
The use of Copalia HCT during breast-feeding is not recommended.
Uporaba zdravila Copalia HCT med dojenjem ni priporočena.
The use of Copalia HCT in children and adolescents under 18 years of age is not recommended.
Pri otrocih in mladostnikih, ki so stari manj kot 18 let, uporaba zdravila Copalia HCT ni priporočena.
The use of Copalia in children and adolescents is not recommended (aged below 18 years old).
Zdravila Copalia ni priporočljivo uporabljati pri otrocih in mladostnikih (starih manj kot 18 let).
The use of Crixivan with ritonavir is based on limited evidence.
Uporaba zdravila Crixivan sočasno z ritonavirjem temelji na omejenih podatkih.
The use of CYSTAGON is contra-indicated during breast-feeding.
Uporaba CYSTAGONa med dojenjem je kontraindicirana.
The use of Dacogen in patients with hepatic impairment has not been established.
Primerne uporabe zdravila Dacogen pri bolnikih z okvaro jeter niso določili.
The use of Dacogen in patients with severe renal impairment has not been studied.
Uporabe zdravila Dacogen pri bolnikih s hudo okvaro ledvic niso proučevali.
The use of Dacogen with hormonal contraceptives has not been studied.
Uporabe zdravila Dacogen s hormonskimi kontraceptivi niso proučevali.
The use of Dafiro HCT during breast-feeding is not recommended.
Uporaba zdravila Dafiro HCT med dojenjem ni priporočena.
The use of Dafiro HCT in children and adolescents under 18 years of age is not recommended.
Pri otrocih in mladostnikih, ki so stari manj kot 18 let, uporaba zdravila Dafiro HCT ni priporočena.
The use of Dafiro in children and adolescents is not recommended (aged below 18 years old).
Zdravila Dafiro ni priporočljivo uporabljati pri otrocih in mladostnikih (starih manj kot 18 let).
The use of dosages which are inadequate or discontinuation of treatment, especially in insulin- dependent diabetics, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.
Posebno pri diabetikih, odvisnih od insulina, lahko uporaba nezadostnih odmerkov ali prenehanje zdravljenja vodi v hiperglikemijo in diabetično ketoacidozo, stanji, ki sta potencialno smrtni.
The use of doses higher than 1.9 g/m2/day is not recommended (see section 4.2).
Uporaba odmerkov, večjih od 1,9 g/m2/dan, ni priporočljiva (glejte poglavje 4.2).
The use of DULOXETINE BOEHRINGER INGELHEIM while breastfeeding is not recommended.
dojiteUporabo zdravila DULOKSETIN BOEHRINGER INGELHEIM v času dojenja odsvetujemo.
The use of Duloxetine Lilly while breastfeeding is not recommended.
Uporabo zdravila Duloxetine Lilly v času dojenja odsvetujemo.
The use of DuoResp Spiromax follows three simple steps: open, breathe and close which are outlined below.
Uporaba zdravila DuoResp Spiromax zajema tri preproste korake: odprite, vdihnite in zaprite, ki so opisani spodaj.
The use of eluxadoline with other medicinal products that may cause constipation (for example anticholinergics, opioids etc) should also be avoided.
Eluksadolin se tudi ne sme uporabljati z drugimi zdravili, ki lahko povzročijo zaprtost (npr. antiholinergiki, opioidi ipd.).
The use of enoxaparin for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied.
Preventivna uporaba enoksaparina za preprečitev tromboze pri nosečnicah z mehaničnimi umetnimi srčnimi zaklopkami še ni dovolj raziskana.
The use of enoxaparin for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied.
Preventivna uporaba enoksaparina za preprečitev tromboze pri nosečnicah z mehaničnimi umetnimi srčnimi zaklopkami še ni zadosti raziskana.
The use of epoetin theta in nephrosclerotic patients not yet undergoing dialysis should be defined individually, as a possible accelerated progression of renal failure cannot be ruled out with certainty.
Uporabo epoetina theta pri bolnikih z nefrosklerozo, ki se še ne zdravijo z dializo, je treba določati individualno, ker morebitnega pospešenega razvoja ledvične odpovedi ni mogoče z gotovostjo izključiti.
The use of EQUIOXX is not permitted in mares producing milk for human consumption.
Uporaba zdravila EQUIOXX ni dovoljena pri kobilah, ki proizvajajo mleko za prehrano ljudi.
The use of erythropoesis stimulating agents was associated with an increased risk of thromboembolic events including pulmonary embolism, acute myocardial infarction, cerebrovascular accident, and deep vein thrombosis.
Uporaba zdravil, ki stimulirajo eritropoezo, je bila povezana s povečanim tveganjem za nastanek tromboemboličnih zapletov, vključno s pljučno embolijo, akutnim miokardnim infarktom, cerebrovaskularnim insultom in globoko vensko trombozo.
The use of eslicarbazepine acetate is associated with increase in the PR interval.
Uporaba eslikarbazepinacetata je povezana s podaljšanjem intervala PR.
The use of Eucreas in children and adolescents up to 18 years of age is not recommended.
Pri otrocih in mladostnikih do 18. leta starosti uporaba zdravila Eucreas ni priporočena.
The use of EVARREST has not been studied in the following procedures, and there is therefore no information to show that it would be effective:
Uporaba zdravila EVARREST v naslednjih posegih še ni bila preučevana, zato ni na voljo nobenih informacij, ki kažejo na njegovo učinkovitost:
The use of EVICEL has not been studied in the following procedures, and there is therefore no information to show that it would be effective in these procedures:
Pri v nadaljevanju naštetih postopkih uporabe zdravila EVICEL niso preučevali, zato ni podatkov, ki bi dokazovali njegovo učinkovitost pri naslednjih postopkih:
The use of Eviplera must be accompanied by the use of effective contraception (see section 4.5).
Pri uporabi zdravila Eviplera je treba uporabljati učinkovito kontracepcijo (glejte poglavje 4.5).
The use of EVOTAZ may be considered during pregnancy only if the potential benefit justifies the potential risk.
Med nosečnostjo se sme zdravilo EVOTAZ uporabljati le, če možne koristi upravičujejo možna tveganja.
The use of Exforge in children and adolescents is not recommended (aged below 18 years old).
Zdravila Exforge ni priporočljivo uporabljati pri otrocih in mladostnikih (starih manj kot 18 let).
The use of EXUBERA in patients requiring dose titrations of less than 1 mg is not recommended (see section 4.4).
EXUBERE ni priporočljivo uporabljati pri bolnikih, ki potrebujejo prilagoditve odmerka, manjše od 1 mg (glejte poglavje 4.4).
The use of eye-protection, gloves and a nose-mouth mask by the operator is advised during administration.
Priporočljiva je uporaba zaščite za oči, rokavic in maske za nos/usta.
The use of fibrinolytic medicinal products for the treatment of acute ischemic stroke may be considered if the patient presents with a dTT, ECT or aPTT not exceeding the ULN according to the local reference range.
O uporabi fibrinolitičnih zdravil za zdravljenje akutne ishemične možganske kapi je treba presoditi, če bolnikove vrednosti dTT, EKT ali aPTČ niso večje od zgornje meje normalnega lokalnega razpona referenčnih vrednosti.
The use of filgrastim-mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.
Ugotovljeno je bilo, da uporaba matičnih celic, izplavljenih s filgrastimom, zmanjša izrazitost in trajanje trombocitopenije po mielosupresivni ali mieloablacijski kemoterapiji.
The use of fluoroquinolones in combination with non-steroidal anti-inflammatory drugs (NSAIDs) may cause seizures.
Kombinacija fluorokinolonov in nestereoidnih antiinflamatorikov (NSAID) lahko pri epilepsiji izzove napad.